Spring has been bountiful at Cleveland's Abeona Therapeutics. | As Abeona gears up for the commercial rollout of Zevaskyn, ...

The U.S. Food and Drug Administration (FDA) has approved prademagene zamikeracel (Zevaskyn) for the treatment of blistering wounds caused by recessive dystrophic epidermolysis bullosa (RDEB) ...

Abeona Therapeutics has secured US Food and Drug Administration (FDA) approval for Zevaskyn (prademagene zamikeracel), a gene-corrected cell therapy designed to treat recessive dystrophic ...

Abeona Therapeutics transitions to a commercial-stage company with ZEVASKYN's FDA approval, QTC activation, and a PRV sale boosting operations toward ...

Abeona Therapeutics Inc. (Nasdaq: ABEO), a Cleveland-based biotech company, announced Monday, May 12, that it has entered an ...

The FDA has approved Abeona Therapeutics’ prademagene zamikeracel (Zevaskyn) gene therapy for recessive dystrophic epidermolysis bullosa (DEB), a rare genetic skin disease. Prademagene ...

The biotech has quickly turned a cell therapy approval into one of the more lucrative recent sales for a priority review ...

Q1 2025 Earnings Call Transcript May 16, 2025 Operator: Good day and welcome to the Abeona Therapeutics First Quarter 2025 ...

On April 29, 2025, Abeona announced approval from the U.S. Food and Drug Administration (FDA) for ZEVASKYN as the first and only autologous cell-based gene therapy for the treatment of wounds in ...

Received approval by U.S. Food and Drug Administration (FDA) for ZEVASKYN™ (prademagenezamikeracel), the first and only ...

ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now ...

Received approval by U.S. Food and Drug Administration (FDA) for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and ...